CLL patients may soon stop daily pills: new combo aims for Fixed-Duration treatment
NCT ID NCT06958705
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding venetoclax (a targeted drug) to ongoing BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve deep remission and then stop all treatment. About 79 adults who have been on a BTK inhibitor for at least 6 months and are still responding will receive venetoclax for 12 cycles. After that, both drugs are stopped and patients are monitored. The goal is to see if this fixed-duration approach can maintain remission without lifelong medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax (a targeted drug) added to a BTK inhibitor (ibrutinib, zanubrutinib, orelabrutinib, or acalabrutinib)
- What this could lead to
- If successful, this approach could allow CLL patients to stop all medication after a fixed treatment period, instead of taking drugs indefinitely.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 79 participants. It may not work for everyone, and side effects from combining two powerful drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.